Vitamin C for Severe Thermal Injuries

• Status: Withdrawn
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Animal and human data have supported the notion that administration of large doses of Vitamin C has beneficial effects on those subjects suffering from large burns. This effect may be due, in part, to the antioxidant and free-radical-scavenging properties of Vitamin C. These studies have demonstrated an improvement in urine output during resuscitation and reduced need for fluid volumes during resuscitation. In turn, these subjects demonstrated a reduction of wound edema, improved respiratory status (demonstrated by improvements in P:F ratios and reduced ventilator days), and no differences in terms of the possible complications of high-dose vitamin C administration between standard and treatment groups. The purpose of this study is to prospectively determine if Vitamin C can be safely used as an adjunctive treatment for patients suffering severe thermal injuries. High-dose vitamin C administered at a dose of 66mg/kg/hr during the acute phase of severe burn injuries will reduce fluid requirements in the first 48 hours after injury.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

1. Subjects presenting with second and/or third degree burns exceeding 20% total body surface area but not greater than 75% TBSA

2. Age between 18 and 65 years of age

3. Subject has provided full written informed consent prior to the performance of any study-related treatment or procedure

Exclusion Criteria:

1. Subjects presenting more than 6 hours from the estimated time of injury

2. Known inclusion in another interventional clinical trial

3. Subjects with known significant comorbidities (Congestive Heart Failure, Myocardial Infarction within 6 months of admission, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease or Renal Impairment)

4. Pregnant Subjects

5. Prisoners or Subjects Under Arrest

6. Subjects younger than 18 years of age or older than 65 years of age

7. Subjects with Baux Scores (Age plus % TBSA) greater than 120 (describing a non-survivable injury)

8. Subjects with any known allergy to components included in injectable ascorbic acid

9. Subjects with significant trauma burden (ISS > 15), including any open fracture, intracranial hemorrhage, or significant intra-abdominal injury.